Education
About Us
Working with TipRanks
Follow Us
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H (HK:2196)
:2196
RESEARCH TOOLSreports
Total Valuation
Shanghai Fosun Pharmaceutical (Group) Co has a market cap or net worth of $61.63B. The enterprise value is ―.
Market Cap$61.63B
Enterprise Value―
Share Statistics
Shanghai Fosun Pharmaceutical (Group) Co has 551,940,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding551,940,500
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Shanghai Fosun Pharmaceutical (Group) Co’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee1.02M
Profits Per Employee58.84K
Employee Count40,557
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Shanghai Fosun Pharmaceutical (Group) Co is ―. Shanghai Fosun Pharmaceutical (Group) Co’s PEG ratio is ―.
PE Ratio―
PS Ratio1.19
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Shanghai Fosun Pharmaceutical (Group) Co had revenue of 41.40B and earned 2.39B in profits. Earnings per share was 0.89.
Revenue41.40B
Gross Profit19.68B
Operating Income3.31B
Pretax Income3.26B
Net Income2.39B
EBITDA7.55B
Earnings Per Share (EPS)0.89
Cash Flow
In the last 12 months, operating cash flow was 2.86B and capital expenditures 0.00, giving a free cash flow of 150.79M billion.
Operating Cash Flow2.86B
Free Cash Flow150.79M
Free Cash Flow per Share0.27
Dividends & Yields
Shanghai Fosun Pharmaceutical (Group) Co pays an annual dividend of HK$0.3, resulting in a dividend yield of 1.97%
Dividend Per ShareHK$0.3
Dividend Yield1.97%
Payout Ratio27.27%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.08
52-Week Price Change26.53%
50-Day Moving Average15.01
200-Day Moving Average14.00
Relative Strength Index (RSI)43.30
Average Volume (3m)5.23M
Important Dates
Shanghai Fosun Pharmaceutical (Group) Co upcoming earnings date is Apr 29, 2025, TBA Not Confirmed.
Last Earnings DateMar 25, 2025
Next Earnings DateApr 29, 2025
Ex-Dividend DateJul 26, 2024
Financial Position
Shanghai Fosun Pharmaceutical (Group) Co as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Shanghai Fosun Pharmaceutical (Group) Co has paid 369.50M in taxes.
Income Tax369.50M
Effective Tax Rate―
Enterprise Valuation
Shanghai Fosun Pharmaceutical (Group) Co EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Shanghai Fosun Pharmaceutical (Group) Co has $15.63B in cash and marketable securities with ¥23.21B in debt, giving a net cash position of $14.14B billion.
Cash & Marketable Securities$15.63B
Total Debt¥23.21B
Net Cash$14.14B
Net Cash Per Share$25.61
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Shanghai Fosun Pharmaceutical (Group) Co is $14.20, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$14.20
Price Target Upside1.61% Upside
Analyst ConsensusHold
Analyst Count0
Revenue Growth Forecast-2.82%
EPS Growth Forecast28.17%